| Primary |
| Drug Use For Unknown Indication |
26.4% |
| Tuberculosis |
25.6% |
| Pulmonary Tuberculosis |
16.5% |
| Product Used For Unknown Indication |
5.0% |
| Antibiotic Prophylaxis |
4.1% |
| Diabetes Mellitus |
3.3% |
| Prophylaxis |
3.3% |
| Adrenal Insufficiency |
1.7% |
| Arthritis |
1.7% |
| Contraception |
1.7% |
| Cough |
1.7% |
| Essential Hypertension |
1.7% |
| Latent Tuberculosis |
1.7% |
| Deep Vein Thrombosis |
0.8% |
| Enteritis |
0.8% |
| Exposure To Communicable Disease |
0.8% |
| Hiv Infection |
0.8% |
| Hypertension |
0.8% |
| Lung Disorder |
0.8% |
| Lymph Node Tuberculosis |
0.8% |
|
| Vomiting |
20.6% |
| Weight Decreased |
8.8% |
| Psoriasis |
5.9% |
| Rash Maculo-papular |
5.9% |
| Sjogren's Syndrome |
5.9% |
| Urticaria |
5.9% |
| Visual Acuity Reduced |
5.9% |
| Weight Increased |
5.9% |
| C-reactive Protein Increased |
2.9% |
| Drug Interaction |
2.9% |
| Facial Palsy |
2.9% |
| Hepatocellular Injury |
2.9% |
| Hyperthyroidism |
2.9% |
| Hypoglycaemia |
2.9% |
| Jaundice Cholestatic |
2.9% |
| Liver Function Test Abnormal |
2.9% |
| Neutropenia |
2.9% |
| No Adverse Event |
2.9% |
| Pancreatitis Acute |
2.9% |
| Panniculitis |
2.9% |
|
| Secondary |
| Drug Use For Unknown Indication |
20.8% |
| Tuberculosis |
18.8% |
| Hiv Infection |
9.6% |
| Ankylosing Spondylitis |
7.1% |
| Product Used For Unknown Indication |
6.6% |
| Rheumatoid Arthritis |
6.1% |
| Prophylaxis |
5.1% |
| Disseminated Tuberculosis |
3.0% |
| Maternal Exposure Timing Unspecified |
2.5% |
| Psoriasis |
2.5% |
| Tuberculin Test Positive |
2.5% |
| Unevaluable Event |
2.5% |
| Cough |
2.0% |
| Pain |
2.0% |
| Renal Failure Chronic |
2.0% |
| Diarrhoea |
1.5% |
| Exposure To Communicable Disease |
1.5% |
| Granuloma |
1.5% |
| Arthralgia |
1.0% |
| Arthritis |
1.0% |
|
| Vomiting |
14.9% |
| Rash Maculo-papular |
12.8% |
| Jaundice |
8.5% |
| Aplasia Pure Red Cell |
6.4% |
| Leukocytoclastic Vasculitis |
6.4% |
| Syncope |
6.4% |
| Cytolytic Hepatitis |
4.3% |
| Drug Eruption |
4.3% |
| Foetal Exposure During Pregnancy |
4.3% |
| Immune Reconstitution Syndrome |
4.3% |
| Oedema Peripheral |
4.3% |
| Paraesthesia |
4.3% |
| Tuberculosis |
4.3% |
| C-reactive Protein Increased |
2.1% |
| Death |
2.1% |
| Drug Exposure During Pregnancy |
2.1% |
| Eye Infection Toxoplasmal |
2.1% |
| Facial Palsy |
2.1% |
| Gamma-glutamyltransferase Increased |
2.1% |
| Hepatitis |
2.1% |
|
| Concomitant |
| Rheumatoid Arthritis |
15.9% |
| Product Used For Unknown Indication |
13.4% |
| Drug Use For Unknown Indication |
13.2% |
| Tuberculosis |
12.5% |
| Hiv Infection |
11.9% |
| Mycobacterial Infection |
6.1% |
| Antibiotic Prophylaxis |
3.8% |
| Type 2 Diabetes Mellitus |
2.3% |
| Ankylosing Spondylitis |
2.1% |
| Osteoporosis |
2.1% |
| Antiviral Prophylaxis |
1.9% |
| Depression |
1.9% |
| Hypertension |
1.9% |
| Pain |
1.9% |
| Prophylaxis |
1.9% |
| Bone Pain |
1.7% |
| Pulmonary Tuberculosis |
1.7% |
| Disseminated Tuberculosis |
1.5% |
| Systemic Lupus Erythematosus |
1.5% |
| Antifungal Prophylaxis |
1.3% |
|
| Vomiting |
9.9% |
| Cytomegalovirus Infection |
8.5% |
| Immune Reconstitution Syndrome |
8.5% |
| Death |
5.6% |
| Hypothermia |
5.6% |
| Lymphoproliferative Disorder |
5.6% |
| Pancreatitis |
5.6% |
| Pancreatitis Acute |
5.6% |
| Ventricular Septal Defect |
5.6% |
| Drug Reaction With Eosinophilia And Systemic Symptoms |
4.2% |
| Interstitial Lung Disease |
4.2% |
| Lymphadenitis |
4.2% |
| Pulmonary Tuberculosis |
4.2% |
| Pyrexia |
4.2% |
| Stillbirth |
4.2% |
| Paraesthesia |
2.8% |
| Premature Baby |
2.8% |
| Pruritus Generalised |
2.8% |
| Pulmonary Embolism |
2.8% |
| Renal Failure |
2.8% |
|
| Interacting |
| Breast Cancer |
15.0% |
| Type 2 Diabetes Mellitus |
15.0% |
| Ankylosing Spondylitis |
10.0% |
| Contraception |
10.0% |
| Product Used For Unknown Indication |
10.0% |
| Pulmonary Tuberculosis |
10.0% |
| Thyroiditis |
10.0% |
| Tuberculosis Skin Test Positive |
10.0% |
| Antibiotic Prophylaxis |
5.0% |
| Tuberculosis |
5.0% |
|
| Hepatitis Acute |
42.9% |
| Unintended Pregnancy |
42.9% |
| Hypoglycaemia |
14.3% |
|
